Glenmark Pharmaceuticals Limited — Updates, 12-03-2025: Press Release

Glenmark Pharmaceuticals has expanded its cardiometabolic portfolio with the launch of Empagliflozin in India, marketed under the brand names Glempa, Glempa-L, and Glempa-M. Empagliflozin, an SGLT2 inhibitor, is recognized for its effectiveness in improving glycemic control, promoting weight loss, and reducing cardiovascular and renal risks in patients with type 2 diabetes mellitus (T2DM). Studies indicate that Empagliflozin significantly lowers HbA1c and fasting blood sugar levels, while also aiding in weight loss. The combination therapies, Glempa-L and Glempa-M, enhance management options for T2DM patients with cardiovascular risks.

This launch aligns with Glenmark's strategy to address the rising prevalence of diabetes and related cardiovascular diseases in India, a market valued at approximately 642 crore for Empagliflozin and its combinations. With the introduction of these products, Glenmark aims to improve health outcomes for a growing patient population, reinforcing its position as a leader in innovative cardiometabolic care solutions. Potential growth is anticipated as these affordable treatments become available to healthcare professionals and patients across the country.